ArticleFrontiers in immunology2025
A nomogram-based radiomics for predicting survival to concurrent chemoradiotherapy in inoperable pancreatic cancer: a dual-center cohort study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction and validation of a nomogram for overall survival prognosis in patients with advanced (stage III/IV) pancreatic cancer.Scientific reports · 2026Article
- Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies.BioFactors (Oxford, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study was designed to explore the value of machine learning-based radiology in predicting overall survival (OS) among patients with inoperable pancreatic cancer (PC) who are undergoing concurrent chemoradiotherapy (CCRT). Methods: This multicenter study enrolled 342 patients with inoperable PC. Firstly, radiomic features were pre-screened by univariate Cox regression and subsequently used to develop 101 machine-learning-based imaging models. An optimized selection algorithm was applied to these models to derive each patient's radiomic signature (Rad-score). Secondly, key clinical predictors of OS were identified via LASSO-Cox regression and incorporated into clinical nomogram. Finally, the Rad-score was combined with the independent clinical risk factors to construct clinical-radiomics nomogram. Results: LASSO-Cox regression identified age, clinical stage, tumor size, and albumin level as independent prognostic factors for OS. Based on these four variables, we constructed a clinical nomogram in the training cohort, which achieved a C-index of 0.71. In the internal validation cohort, the areas under the receiver operating characteristic curve (AUC-ROC) for predicting 1-, 2-, and 3-year OS were 0.577, 0.721, and 0.730, respectively; in the external validation cohort, the corresponding AUC-ROCs were 0.841, 0.757, and 0.598. Subsequently, each patient's Rad-score was integrated with these clinical predictors to develop a clinical-radiomics nomogram, which demonstrated a C-index of 0.892. The AUC-ROCs for predicting 1-, 2-, and 3-year OS were 0.791, 0.846, and 0.840 in the internal validation cohort, and 0.863, 0.830, and 0.734 in the external validation cohort. Conclusion: The clinical-radiomics nomogram demonstrated superior predictive performance for OS compared to the clinical nomogram in inoperable PC patients undergoing CCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.